Should you buy Ascendis Pharma stock now?
The technical signal for Ascendis Pharma is currently NEUTRAL. Ascendis Pharma trades at $0.00 as of 8/28/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -0.196 with falling momentum (signal: -0.080); RSI is at 46.8 (neutral zone). This is a technical observation based on current data, not investment advice.
What is the price target for Ascendis Pharma stock?
There is currently no active analyst price target for Ascendis Pharma.
Is Ascendis Pharma a dividend stock?
No, Ascendis Pharma does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Ascendis Pharma stock?
Ascendis Pharma is rated as a stock in the risk category Moderate. the annual standard deviation is 36.7%, which classifies the stock as Moderate.
Is Ascendis Pharma overvalued?
Ascendis Pharma has the following valuation ratios: a P/E ratio of 19.2 (moderately valued), a P/S ratio of 15.7, a P/B ratio of 9.9.
Is Ascendis Pharma overbought?
No, Ascendis Pharma is not overbought. RSI is at 46.8 (neutral zone). The technical indicators show: RSI is at 46.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, MACD is negative with falling momentum (bearish).
When is the next Ascendis Pharma earnings report?
The date of the next earnings report for Ascendis Pharma has not been published yet. Check the company's investor calendar for updates.
Is Ascendis Pharma shorted?
Yes, Ascendis Pharma is shorted with 6.7% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Ascendis Pharma stock?
Yes, insiders are net buyers of Ascendis Pharma – they are buying more shares than they are selling. Over the last 3 months, insiders have made 2 purchases and 0 sales. On a net basis, 293,501 $ worth of shares were bought. Across the last 6 reported transactions, the split is 5 purchases and 1 sales, with a net 4,199,110 $ sold. Active buyers include BIENAIME JEAN JACQUES, SMITH SCOTT THOMAS. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Ascendis Pharma a good stock?
Based on our total score, Ascendis Pharma is rated as a good stock with a total score of 66 out of 100. The stock scores above average on value, quality and momentum – it is among the top 34% in our database. The score is made up of Value: 41/100, Quality: 98/100, Momentum: 58/100. In addition: technical signal: Hold. Whether Ascendis Pharma is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Ascendis Pharma stock?
The outlook for Ascendis Pharma based on current data: the P/E ratio is 19.2 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Ascendis Pharma stock moving?
Ascendis Pharma is moving right now. The technical indicators show: MACD is negative with falling momentum (bearish signal); short interest is 6.7% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Ascendis Pharma go?
There is currently no active analyst price target for Ascendis Pharma. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Ascendis Pharma fall?
We lack enough history to give a specific floor for Ascendis Pharma. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Ascendis Pharma do?
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficienc... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Ascendis Pharma as an investment.
Did Ascendis Pharma raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Ascendis Pharma. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Ascendis Pharma making money or losing money?
Yes, Ascendis Pharma is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 70.9% — which is excellent. The operating margin (profit before interest and taxes) is 65.0%. At a P/E ratio of 19.2, you currently pay 19.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Ascendis Pharma go bankrupt?
The bankruptcy risk of Ascendis Pharma is rated as moderate. Altman Z2 (a model for assessing financial distress) is 1.93 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Ascendis Pharma have a lot of debt?
Yes, Ascendis Pharma has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Ascendis Pharma service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 4.4x, and the company has more cash than debt (net cash).